Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Thorax ; 74(4): 354-361, 2019 04.
Artículo en Inglés | MEDLINE | ID: mdl-30661019

RESUMEN

PURPOSE: Malignant pleural mesothelioma (MPM) has a high symptom burden and poor survival. Evidence from other cancer types suggests some benefit in health-related quality of life (HRQoL) with early specialist palliative care (SPC) integrated with oncological services, but the certainty of evidence is low. METHODS: We performed a multicentre, randomised, parallel group controlled trial comparing early referral to SPC versus standard care across 19 hospital sites in the UK and one large site in Western Australia. Participants had newly diagnosed MPM; main carers were additionally recruited. INTERVENTION: review by SPC within 3 weeks of allocation and every 4 weeks throughout the study. HRQoL was assessed at baseline and every 4 weeks with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30. PRIMARY OUTCOME: change in EORTC C30 Global Health Status 12 weeks after randomisation. RESULTS: Between April 2014 and October 2016, 174 participants were randomised. There was no significant between group difference in HRQoL score at 12 weeks (mean difference 1.8 (95% CI -4.9 to 8.5; p=0.59)). HRQoL did not differ at 24 weeks (mean difference -2.0 (95% CI -8.6 to 4.6; p=0.54)). There was no difference in depression/anxiety scores at 12 weeks or 24 weeks. In carers, there was no difference in HRQoL or mood at 12 weeks or 24 weeks, although there was a consistent preference for care, favouring the intervention arm. CONCLUSION: There is no role for routine referral to SPC soon after diagnosis of MPM for patients who are cared for in centres with good access to SPC when required. TRIAL REGISTRATION NUMBER: ISRCTN18955704.


Asunto(s)
Neoplasias Pulmonares/rehabilitación , Mesotelioma/rehabilitación , Cuidados Paliativos/organización & administración , Neoplasias Pleurales/rehabilitación , Calidad de Vida , Anciano , Cuidadores/psicología , Femenino , Humanos , Masculino , Mesotelioma Maligno , Cooperación del Paciente , Psicometría , Derivación y Consulta/organización & administración , Factores de Tiempo , Reino Unido , Australia Occidental
2.
N Engl J Med ; 365(6): 518-26, 2011 Aug 11.
Artículo en Inglés | MEDLINE | ID: mdl-21830966

RESUMEN

BACKGROUND: More than 30% of patients with pleural infection either die or require surgery. Drainage of infected fluid is key to successful treatment, but intrapleural fibrinolytic therapy did not improve outcomes in an earlier, large, randomized trial. METHODS: We conducted a blinded, 2-by-2 factorial trial in which 210 patients with pleural infection were randomly assigned to receive one of four study treatments for 3 days: double placebo, intrapleural tissue plasminogen activator (t-PA) and DNase, t-PA and placebo, or DNase and placebo. The primary outcome was the change in pleural opacity, measured as the percentage of the hemithorax occupied by effusion, on chest radiography on day 7 as compared with day 1. Secondary outcomes included referral for surgery, duration of hospital stay, and adverse events. RESULTS: The mean (±SD) change in pleural opacity was greater in the t-PA-DNase group than in the placebo group (-29.5±23.3% vs. -17.2±19.6%; difference, -7.9%; 95% confidence interval [CI], -13.4 to -2.4; P=0.005); the change observed with t-PA alone and with DNase alone (-17.2±24.3 and -14.7±16.4%, respectively) was not significantly different from that observed with placebo. The frequency of surgical referral at 3 months was lower in the t-PA-DNase group than in the placebo group (2 of 48 patients [4%] vs. 8 of 51 patients [16%]; odds ratio for surgical referral, 0.17; 95% CI, 0.03 to 0.87; P=0.03) but was greater in the DNase group (18 of 46 patients [39%]) than in the placebo group (odds ratio, 3.56; 95% CI, 1.30 to 9.75; P=0.01). Combined t-PA-DNase therapy was associated with a reduction in the hospital stay, as compared with placebo (difference, -6.7 days; 95% CI, -12.0 to -1.9; P=0.006); the hospital stay with either agent alone was not significantly different from that with placebo. The frequency of adverse events did not differ significantly among the groups. CONCLUSIONS: Intrapleural t-PA-DNase therapy improved fluid drainage in patients with pleural infection and reduced the frequency of surgical referral and the duration of the hospital stay. Treatment with DNase alone or t-PA alone was ineffective. (Funded by an unrestricted educational grant to the University of Oxford from Roche UK and by others; Current Controlled Trials number, ISRCTN57454527.).


Asunto(s)
Desoxirribonucleasas/uso terapéutico , Fibrinolíticos/uso terapéutico , Enfermedades Pleurales/tratamiento farmacológico , Derrame Pleural/tratamiento farmacológico , Activador de Tejido Plasminógeno/uso terapéutico , Adulto , Anciano , Desoxirribonucleasas/efectos adversos , Método Doble Ciego , Femenino , Fibrinolíticos/efectos adversos , Humanos , Instilación de Medicamentos , Análisis de Intención de Tratar , Modelos Lineales , Pulmón/diagnóstico por imagen , Masculino , Persona de Mediana Edad , Enfermedades Pleurales/diagnóstico por imagen , Enfermedades Pleurales/mortalidad , Derrame Pleural/diagnóstico por imagen , Radiografía , Activador de Tejido Plasminógeno/efectos adversos
3.
Intensive Care Med ; 30(1): 68-74, 2004 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-14634726

RESUMEN

OBJECTIVE: To examine whether cytokine concentrations change in the pulmonary compartment during the development of ventilator-associated pneumonia (VAP). DESIGN: Non-directed bronchial lavage (NBL) was performed every 48 h in critically ill mechanically ventilated patients. Serial measurements of the cytokines tumor necrosis factor (TNF) alpha, interleukin (IL)-1alpha, IL-1beta, IL-6, and IL-10 and the cytokine inhibitors soluble TNFalpha receptor type I (sTNFalphaRI), IL-1 receptor antagonist (IL-1Ra) and soluble IL-1 receptor II (sIL-1RII) were performed on the NBL fluid and matching plasma samples by ELISA. SETTING: An adult medical and surgical university hospital intensive care unit. PATIENTS: Nine patients who developed VAP and nineteen patients who did not develop VAP served as controls. INTERVENTIONS: None. RESULTS: Plasma concentrations of the measured cytokines and cytokine inhibitors did not change significantly in any patients. In control patients, NBL fluid concentrations of sIL-1RII decreased significantly over time (P=0.01). In patients who developed VAP, NBL fluid concentrations of TNFalpha, sTNFalphaRI, IL-1alpha, and IL-1beta increased significantly (P=0.002, P=0.03, P=0.04 and P=0.02, respectively). Furthermore, NBL fluid/plasma concentration ratios for TNFalpha, sTNFalphaRI, IL-1alpha, IL-1Ra and IL-6 increased significantly as VAP developed (P=0.001, P=0.001, P=0.04, P=0.03, and P=0.04, respectively). CONCLUSION: Our results suggest that the production of important cytokines and cytokine inhibitors is compartmentalised within the lung in critically ill mechanically ventilated patients who develop VAP.


Asunto(s)
Líquido del Lavado Bronquioalveolar/citología , Citocinas/análisis , Citocinas/sangre , Neumonía Bacteriana/sangre , Neumonía Bacteriana/etiología , Respiración Artificial/efectos adversos , Adulto , Anciano , Antígenos CD/análisis , Antígenos CD/sangre , Compartimentos de Líquidos Corporales , Estudios de Casos y Controles , Citocinas/antagonistas & inhibidores , Citocinas/inmunología , Inglaterra , Ensayo de Inmunoadsorción Enzimática , Femenino , Hospitales Universitarios , Humanos , Proteína Antagonista del Receptor de Interleucina 1 , Interleucina-1/análisis , Interleucina-1/sangre , Interleucina-10/análisis , Interleucina-10/sangre , Interleucina-6/análisis , Interleucina-6/sangre , Modelos Lineales , Masculino , Persona de Mediana Edad , Neumonía Bacteriana/inmunología , Receptores de Interleucina-1/análisis , Receptores de Interleucina-1/sangre , Receptores Tipo I de Interleucina-1 , Receptores del Factor de Necrosis Tumoral/análisis , Receptores del Factor de Necrosis Tumoral/sangre , Receptores Tipo I de Factores de Necrosis Tumoral , Sialoglicoproteínas/análisis , Sialoglicoproteínas/sangre , Factores de Tiempo , Factor de Necrosis Tumoral alfa/análisis , Factor de Necrosis Tumoral alfa/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA